Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AMINOSYN II 3.5% is an injectable amino acid formulation used for parenteral nutrition support in hospitalized and critically ill patients. It provides essential and non-essential amino acids to maintain protein synthesis and metabolic function when oral or enteral nutrition is not feasible. The product works by supplying exogenous amino acids to prevent catabolism and support wound healing and immune function.
Product is in late-stage lifecycle with approaching loss of exclusivity; commercial teams should expect consolidation and transition planning within 2-3 years.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
The Glucagonotropic Effect of Amino Acids in Humans
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)
Bioavailability of Plant Protein Amino Acids
Worked on AMINOSYN II 3.5% at ICU Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on AMINOSYN II offers stability in a mature institutional/hospital market but limited growth upside given LOE approaching status and zero linked job openings. Career advancement requires focus on cost optimization, customer retention, and transition planning rather than market expansion.